Inflammatory mediators and posterior segment involvement in ocular Behçet disease

European Journal of Ophthalmology

Volumn 19, Issue 6, 2009, Pages 998-1003

  Ozdamar, Yasemin ^a   Berker, Nilufer ^a   Bahar, Gul ^b   Soykan, Emel ^a   Bicer, Tolga ^a   Ozkan, Seyhan Sonar ^a   Karakaya, Jale ^c  

^a Ankara Ulucanlar Eye Research Hospital   (Turkey)

^b Diskapi Education and Research Hospital   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Beh et disease; Inflammatory mediators; Posterior segment; Uveitis

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTACOID; INTERLEUKIN DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; FEMALE; HUMAN; MALE; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; RETINA EDEMA; SPECTROPHOTOMETRY; UVEITIS; BLOOD; MIDDLE AGED; NONPARAMETRIC TEST; PROSPECTIVE STUDY;

ADULT; BEHCET SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKINS; MALE; MALONDIALDEHYDE; MIDDLE AGED; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, POSTERIOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 73949145496     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900616     Document Type: Article

References (25)

1. Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behçet's disease: from Hippocrates to the third millennium. Br J Ophthalmol 2003; 87: 1175-83.
2. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol 1997; 14: 67-79.
3. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005; 50: 297-350.
4. Rajendram R, Rao NA. Molecular mechanisms in Behçet's disease. Br J Ophthalmol 2003; 87: 1199-200.
5. Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986; 70: 589-92.
6. Kansu T, Kadayifcilar S. Visual aspects of Behçet's disease. Curr Neurol Neurosci Rep 2005; 5: 382-8.
7. Ozdal PC, Ortac S, Taskintuna I, Firat E. Posterior segment involvement in ocular Behçet's disease. Eur J Ophthalmol 2002; 12: 424-31.
8. The International Study Group for Behçet's disease. Evaluation of diagnostic ('classification') criteria in Behçet's disease - towards internationally agreed criteria. Br J Rheumatol 1992; 31: 299-308.
9. Taysi S, Kocer I, Memisogullari R, Kiziltunc A. Serum oxidant/antioxidant status in patients with Behçet's disease. Ann Clin Lab Sci 2002; 32: 377-82.
10. Aydin E, Sogut S, Ozyurt H, Ozugurlu F, Akyol O. Comparison of serum nitric oxide, malondialdehyde levels, and antioxidant enzyme activities in Behçet's disease with and without ocular disease. Ophthalmic Res 2004; 36: 177-82.
11. Buldanlioglu S, Turkmen S, Ayabakan HB, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease. Br J Dermatol 2005; 153: 526-30.
12. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002; 11: 87-93.
13. Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behçet's disease. Br J Ophthalmol 2004; 88: 1256-8.
14. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm 2004; 12: 53-8.
15. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001; 33: 251-5.
16. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36.
17. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84: 1045-9.
18. Kaburaki T, Fujino Y, Kawashima H, et al. Plasma and whole-blood chemokine levels in patients with Behçet's disease. Graefes Arch Clin Exp Ophthalmol 2003; 241: 353-8.
19. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades- Behçet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000; 201: 37-9.
20. Gur-Toy G, Lenk N, Yalcin B, Aksaray S, Alli N. Serum interleukin-8 as a serologic marker of activity in Behçet's disease. Int J Dermatol 2005; 44: 657-60.
21. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
22. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-70.
23. Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Int J Dermatol 2003; 42: 870-5.
24. O'Duffy JD. Vasculitis in Behçet's disease. Rheum Dis Clin North Am 1990; 16: 423-31.
25. Bozoglu E, Dinc A, Erdem H, Pay S, Simsek I, Kocar IH. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis. Clin Exp Rheumatol 2005; 23 (Suppl): S42-8.